Back to top
more

Insulet (PODD)

(Delayed Data from NSDQ)

$166.19 USD

166.19
636,152

+2.02 (1.23%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $166.26 +0.07 (0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth C Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 44% (142 out of 252)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for PODD

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Insulet Corporation [PODD]

Reports for Purchase

Showing records 321 - 340 ( 340 total )

Company: Insulet Corporation

Industry: Medical - Products

Record: 321

06/21/2011

Company Report

Pages: 5

Moving to 2nd Gen Approval

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 322

05/10/2011

Company Report

Pages: 5

Q1 Meets Expectations - Raising PT To $25

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 323

05/02/2011

Daily Note

Pages: 12

Medical Device Q1 Earnings Preview

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 324

02/22/2011

Company Report

Pages: 5

Q4 Revenues Grow 37% - Raising Target Price To $22 - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 325

02/22/2011

Company Report

Pages: 5

Q4 Revenues Grow 37% - Raising Target Price To $22 - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 326

02/15/2011

Company Report

Pages: 6

In-Line Q4-10; Banking on the next-gen OmniPod; Maintain Market Perform

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 327

02/15/2011

Daily Note

Pages: 3

In-Line Q4-10; Banking on the next-gen OmniPod; Maintain Market Perform

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 328

02/14/2011

Company Report

Pages: 5

EXPECTING INLINE QUARTER

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 329

11/11/2010

Industry Report

Pages: 8

INCREASED FDA SCRUTINY LEADING TO LONGER APPROVAL TIMES

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 330

11/11/2010

Daily Note

Pages: 7

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 331

11/10/2010

Company Report

Pages: 5

MEETS Q3 EXPECTATIONS -MGT TIGHTENS GUIDANCE NO CHANGE ESTIMATE - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 332

11/10/2010

Company Report

Pages: 3

In-Line Q3-10; Regulatory headwinds could pose problems; Maintain Market Perform

Provider: RODMAN & RENSHAW, CO.

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 333

08/26/2010

Daily Note

Pages: 21

THE NEXT PERFECT STORM-OBAMACARE WILL STRETCH THE SYSTEM TO ITS ULTIMATE LIMIT

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 334

08/02/2010

Daily Note

Pages: 8

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 335

07/30/2010

Company Report

Pages: 3

In-Line Q2-10; In-Line Fiscal 2010 Guidance; Maintain Market Perform

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 336

07/30/2010

Company Report

Pages: 5

REVENUES AT TOP END OF RANGE

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 10.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 337

06/28/2010

Industry Report

Pages: 6

70TH ANNUALAMERICAN DIABETES ASSOCIATION MEETING CONFIRMS THESIS - BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 25.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 338

06/15/2010

Company Report

Pages: 24

INITIATING WITH BUY

Provider: CAPSTONE INVESTMENTS

Analyst: PUTNAM J

Price: 75.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 339

05/07/2010

Daily Note

Pages: 14

MORNING SUMMARY

Provider: RODMAN & RENSHAW, CO.

Price: 50.00

Research Provided by a Third Party

Company: Insulet Corporation

Industry: Medical - Products

Record: 340

05/07/2010

Company Report

Pages: 3

In-Line Q1-10; In-Line Fiscal 2010 Guidance; Maintain Market Perform

Provider: RODMAN & RENSHAW, CO.

Analyst: KALIA S

Price: 10.00

Research Provided by a Third Party